Henagliflozin

Henagliflozin
Clinical data
Trade namesRui Qin; 瑞沁
Other namesSHR3824; SHR-3824
Legal status
Legal status
  • Rx in China
Identifiers
  • (1R,2S,3S,4R,5R)-5-[4-Chloro-3-[(4-ethoxy-3-fluorophenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC22H24ClFO7
Molar mass454.88 g·mol−1
3D model (JSmol)
  • CCOC1=C(C=C(C=C1)CC2=C(C=CC(=C2)[C@]34[C@@H]([C@H]([C@@H]([C@](O3)(CO4)CO)O)O)O)Cl)F
  • InChI=1S/C22H24ClFO7/c1-2-29-17-6-3-12(8-16(17)24)7-13-9-14(4-5-15(13)23)22-20(28)18(26)19(27)21(10-25,31-22)11-30-22/h3-6,8-9,18-20,25-28H,2,7,10-11H2,1H3/t18-,19-,20+,21+,22+/m0/s1
  • Key:HYTPDMFFHVZBOR-VNXMGFANSA-N

Henagliflozin is a pharmaceutical drug for the treatment of type 2 diabetes.[1] In China, it is approved for adult patients with type 2 diabetes to improve the glycemic control.[2][3]

Henagliflozin, like other drugs of the gliflozin class, inhibits the transporter protein sodium/glucose cotransporter 2 (SGLT2) which leads to a reduction in blood glucose levels.[4]

In a 26-week placebo-controlled trial of type 2 diabetics, telomere length significantly lengthened, the IGF-1 pathway was inhibited, and immune system function was improved in the henagliflozin group compared to the placebo group.[5]

References

  1. ^ Weng J, Zeng L, Zhang Y, Qu S, Wang X, Li P, et al. (August 2021). "Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial". Diabetes, Obesity & Metabolism. 23 (8): 1754–1764. doi:10.1111/dom.14389. PMID 33769656.
  2. ^ Wang G (17 February 2022). "Monthly Report: New Drug Approvals in China, January 2022". BaiPharm. Henagliflozin Proline Tablets
  3. ^ "Henagliflozin - Jiangsu HengRui Medicine". AdisInsight. Springer Nature Switzerland AG.
  4. ^ He X, Liu G, Chen X, Wang Y, Liu R, Wang C, et al. (July 2023). "Pharmacokinetic and Pharmacodynamic Interactions Between Henagliflozin, a Novel Selective SGLT-2 Inhibitor, and Warfarin in Healthy Chinese Subjects". Clinical Therapeutics. 45 (7): 655–661. doi:10.1016/j.clinthera.2023.06.002. PMID 37451912.
  5. ^ Zhang J, Cai H, Xu J (2025). "Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study". Cell Reports. 6 (9) 102331. doi:10.1016/j.xcrm.2025.102331. PMC 12490245. PMID 40912255.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.